Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials
Vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies e...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2017/3736201 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849410032361275392 |
|---|---|
| author | Ana Paula Ferreira Costa Ricardo Ney Oliveira Cobucci Janine Medeiros da Silva Paulo Henrique da Costa Lima Paulo César Giraldo Ana Katherine Gonçalves |
| author_facet | Ana Paula Ferreira Costa Ricardo Ney Oliveira Cobucci Janine Medeiros da Silva Paulo Henrique da Costa Lima Paulo César Giraldo Ana Katherine Gonçalves |
| author_sort | Ana Paula Ferreira Costa |
| collection | DOAJ |
| description | Vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies evaluating its safety are rare. Thus, we performed a meta-analysis of three clinical trials assessing adverse effects on women randomly vaccinated with HPV9 or tetravalent vaccine (HPV4), with the objective of analyzing whether the HPV9 is as safe as HPV4. An electronic data search was performed through the PubMed, Embase, Scopus, Web of Science, and SciELO databases. The studies selected 27,465 women who received one of the two vaccines. Pain (OR 1.72; 95% CI 1.62–1.82) and erythema (OR 1.29; 95% CI 1.21–1.36) occurred significantly more in the HPV9 group. However, there was no significant difference between the groups for the following adverse effects: headache (OR 1.07; 95% CI 0.99–1.15), dizziness (OR 1.09; 95% CI 0.93–1.27), and fatigue (OR 1.09; 95% CI 0.91–1.30), and the occurrence of serious events related to vaccination was similarly rare among those vaccinated. Therefore, our findings demonstrate that HPV9 in female patients is as safe as the tetravalent vaccine. |
| format | Article |
| id | doaj-art-765787b0942242d19bee2a3c4552c550 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-765787b0942242d19bee2a3c4552c5502025-08-20T03:35:18ZengWileyJournal of Immunology Research2314-88612314-71562017-01-01201710.1155/2017/37362013736201Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized TrialsAna Paula Ferreira Costa0Ricardo Ney Oliveira Cobucci1Janine Medeiros da Silva2Paulo Henrique da Costa Lima3Paulo César Giraldo4Ana Katherine Gonçalves5Postgraduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, RN, BrazilDepartment of Gynecology and Obstetrics, University Potiguar (UnP), Natal, RN, BrazilDepartment of Gynecology and Obstetrics, Federal University of Rio Grande do Norte (UFRN), Natal, RN, BrazilDepartment of Gynecology and Obstetrics, Federal University of Rio Grande do Norte (UFRN), Natal, RN, BrazilDepartment of Gynecology and Obstetrics, State University of Campinas (UNICAMP), Campinas, SP, BrazilPostgraduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, RN, BrazilVaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies evaluating its safety are rare. Thus, we performed a meta-analysis of three clinical trials assessing adverse effects on women randomly vaccinated with HPV9 or tetravalent vaccine (HPV4), with the objective of analyzing whether the HPV9 is as safe as HPV4. An electronic data search was performed through the PubMed, Embase, Scopus, Web of Science, and SciELO databases. The studies selected 27,465 women who received one of the two vaccines. Pain (OR 1.72; 95% CI 1.62–1.82) and erythema (OR 1.29; 95% CI 1.21–1.36) occurred significantly more in the HPV9 group. However, there was no significant difference between the groups for the following adverse effects: headache (OR 1.07; 95% CI 0.99–1.15), dizziness (OR 1.09; 95% CI 0.93–1.27), and fatigue (OR 1.09; 95% CI 0.91–1.30), and the occurrence of serious events related to vaccination was similarly rare among those vaccinated. Therefore, our findings demonstrate that HPV9 in female patients is as safe as the tetravalent vaccine.http://dx.doi.org/10.1155/2017/3736201 |
| spellingShingle | Ana Paula Ferreira Costa Ricardo Ney Oliveira Cobucci Janine Medeiros da Silva Paulo Henrique da Costa Lima Paulo César Giraldo Ana Katherine Gonçalves Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials Journal of Immunology Research |
| title | Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials |
| title_full | Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials |
| title_fullStr | Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials |
| title_full_unstemmed | Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials |
| title_short | Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials |
| title_sort | safety of human papillomavirus 9 valent vaccine a meta analysis of randomized trials |
| url | http://dx.doi.org/10.1155/2017/3736201 |
| work_keys_str_mv | AT anapaulaferreiracosta safetyofhumanpapillomavirus9valentvaccineametaanalysisofrandomizedtrials AT ricardoneyoliveiracobucci safetyofhumanpapillomavirus9valentvaccineametaanalysisofrandomizedtrials AT janinemedeirosdasilva safetyofhumanpapillomavirus9valentvaccineametaanalysisofrandomizedtrials AT paulohenriquedacostalima safetyofhumanpapillomavirus9valentvaccineametaanalysisofrandomizedtrials AT paulocesargiraldo safetyofhumanpapillomavirus9valentvaccineametaanalysisofrandomizedtrials AT anakatherinegoncalves safetyofhumanpapillomavirus9valentvaccineametaanalysisofrandomizedtrials |